{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:29:57Z","timestamp":1776101397697,"version":"3.50.1"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,4,1]]},"DOI":"10.2169\/internalmedicine.2284-23","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T22:12:29Z","timestamp":1691532749000},"page":"993-998","source":"Crossref","is-referenced-by-count":1,"title":["Hodgkin Lymphoma-related Inflammatory Modification-displayed Castleman Disease-like Histological Features and Positron Emission Tomography\/Computed Tomography Usefulness for the Differential Diagnosis"],"prefix":"10.2169","volume":"63","author":[{"given":"Hirofumi","family":"Yamauchi","sequence":"first","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Momoki","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Kamiyama","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahiro","family":"Gunji","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Boutboul","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, H\u00f4pital Saint-Louis, Assistance Publique H\u00f4pitaux de Paris (APHP), France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Oksenhendler","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, H\u00f4pital Saint-Louis, Assistance Publique H\u00f4pitaux de Paris (APHP), France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hodgkin. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 17: 68-114, 1832.","DOI":"10.1177\/095952873201700106"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood 135: 1353-1364, 2020.","DOI":"10.1182\/blood.2019000931"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nagel S, Scherr M, Quentmeier H, et al. HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia 19: 841-846, 2005.","DOI":"10.1038\/sj.leu.2403716"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Oksenhendler E, Boutboul D, Fajgenbaum D, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 180: 206-216, 2018.","DOI":"10.1111\/bjh.15019"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32: 3059-3068, 2014.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"6","unstructured":"6. Hasenclever D, Diehl V; International Prognostic Factors Project on Advanced Hodgkin&apos;s Disease. A prognostic score for advanced Hodgkin&apos;s disease. N Engl J Med 339: 1506-1514, 1998."},{"key":"7","unstructured":"7. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th (revised) ed. Swerdlow SH, Campo E, Harris NL, et al., Eds. World Health Organisation, Lyon, 2017."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ye B, Gao SG, Li W, et al. A retrospective study of unicentric and multicentric Castleman&apos;s disease: a report of 52 patients. Med Oncol 27: 1171-1178, 2010.","DOI":"10.1007\/s12032-009-9355-0"},{"key":"9","unstructured":"9. Yoshizaki K. [A reference guide for management of Castleman disease]. Rinsho Ketsueki (Jpn J Clin Hematol) 58: 97-107, 2017."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fujimoto S, Koga T, Kawakami A, et al. Tentative diagnostic criteria and disease severity classification for Castleman disease: a report of the research group on Castleman disease in Japan. Mod Rheumatol 28: 161-167, 2018.","DOI":"10.1080\/14397595.2017.1366093"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29: 670-683, 1972.","DOI":"10.1002\/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106: 2627-2632, 2005.","DOI":"10.1182\/blood-2004-12-4602"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hirano T. Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias. Int J Cell Cloning 9: 166-184, 1991.","DOI":"10.1002\/stem.5530090303"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gholiha AR, Hollander P, Glimelius I, et al. Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma. Blood Adv 5: 1671-1681, 2021.","DOI":"10.1182\/bloodadvances.2020003664"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Park J, Lee JE, Kim M, et al. Discordant lymphocyte-depleted classical Hodgkin&apos;s and peripheral T-cell lymphoma arising in a patient 11 years after diagnosis of multicentric Castleman&apos;s disease. Int J Hematol 98: 114-121, 2013.","DOI":"10.1007\/s12185-013-1358-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman&apos;s disease: a systematic review of 404 published cases. Ann Surg 255: 677-684, 2012.","DOI":"10.1097\/SLA.0b013e318249dcdc"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lyapichev KA, You MJ, Vega F, Solis LM, Medeiros LJ. Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging. Virchows Arch 477: 437-444, 2020.","DOI":"10.1007\/s00428-020-02788-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mohtaram A, Afif M, Sghiri T, et al. Coexistence of Hodgkin&apos;s lymphoma and Castleman&apos;s disease: a case report with successful response to chemotherapy and radiotherapy. Case Rep Oncol Med 2013: 487205, 2013.","DOI":"10.1155\/2013\/487205"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Filliatre-Clement L, Busby-Venner H, Moulin C, Roth-Guepin G, Perrot A. Hodgkin lymphoma and Castleman disease: when one blood disease can hide another. Case Rep Hematol 2017: 9423205, 2017.","DOI":"10.1155\/2017\/9423205"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/7\/63_2284-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T03:37:52Z","timestamp":1712374672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/7\/63_2284-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2284-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]},"article-number":"2284-23"}}